Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determining the Genetic Profile in Semen Donors With Pregnancy, Donor Versus no Pregnancy Obtained in TRA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02671344
Recruitment Status : Terminated (could not be obtained enough sperm RNA is highly fragmented and very difficult to purify.)
First Posted : February 2, 2016
Last Update Posted : February 12, 2020
Sponsor:
Collaborator:
Fundación IVI
Information provided by (Responsible Party):
IVI Bilbao

Brief Summary:

Microarray experiments to assess the expression of thousands of genes providing vast amount of information.

Because the molecular requirements in the different processes related to playback,on the hypothesis that there may be more apt semen samples for technical or other assuming molecular differences in RNA content messengers or gene expression profile between the They getting semen samples in gestation versus those who do not.

In an attempt to give a functional data obtained view, it is to find out how many of these genes in donors who have obtained gestation, they are differentially expressed in playback related processes against those donors who did not get pregnant.


Condition or disease Intervention/treatment
Donor Site Complication Other: Determination of gene profiles using arrays semen

Detailed Description:

MRNA assembly is characterized by using microarrays on semen samples from donors included in the donation program of the clinic.

This process is performed in donors who have generated at least 3 pregnancies compared those samples, however, were not a function of gestation assisted reproduction technique used.

Consequently, differential expression of genes are identified in assisted reproduction treatment cycles from IAD, IVF or ICSI.

Layout table for study information
Study Type : Observational
Actual Enrollment : 14 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Determination of Gene Profiling in Semen Donors With Pregnancy Versus no Donor Gestation, Obtained in Assisted Reproduction Treatments
Actual Study Start Date : April 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
IAD group
Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
Other: Determination of gene profiles using arrays semen
Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.

FIV group
Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
Other: Determination of gene profiles using arrays semen
Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.

ICSI group
Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
Other: Determination of gene profiles using arrays semen
Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.




Primary Outcome Measures :
  1. Detecting gene expression differences in RNA content messengers or gene expression profile between the semen samples versus those who get pregnant when you do not. [ Time Frame: 15 months ]

    mRNA whole is characterized by using microarrays, in semen samples from donors included in the donation program of the clinic.

    By using bioinformatics tools Gene Ontology search listings of genes related to reproduction for the interpretation and identification of those who are involved in the different processes will be performed



Biospecimen Retention:   Samples With DNA
Determination of gene profiles characterizing the set of mRNA from donor seminal samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Open retrospective study of 30 semen donors. Comparisons were made of gene expression profile between the IAD, IVF and ICSI groups according to the clinical outcomes of pregnancy.

  • The donor recruitment will be made according to standard protocols rather Bilbao IVI centers will no visit, checking out additional analytical donation program to the donor is attached.
  • By SIVIS data base, the results of different gestation is collected reproductive treatments that allow the allocation to the comparison groups gene profile.
Criteria

Inclusion Criteria:

IAD group Younger than 37 years, natural cycles and stimulated apparently no problem of infertility as follows:

  • Polycystic ovary syndrome.
  • Endometriosis.
  • ovarian failure.
  • Lack of tubal patency (Both fallopian tubes must submit permeability).
  • altered hormonal profiles (High levels of FSH, LH, testosterone and androstenedione).
  • Anovulation.
  • Uterine malformations (uterine septum, bicorne, didelphic and unicorn.)
  • Ovarian cysts or tumors.
  • Pelvic inflammatory disease.
  • Obesity (Women with a BMI> 30).
  • Thyroid Disease.
  • Diabetes mellitus.
  • renal or adrenal disease.
  • toxic habits (smoking, alcohol or drug abuse).

IVF group Couples who undergo IVF egg donation invoking the program. Therefore, they try to cycles in which two gametes were donors. All egg donors should be fertility proven, it is that must have been able to take shape within the program of egg donation or naturally. The recipient women (patients) should not present

  • Endometriosis.
  • Uterine malformations (uterine septum, bicorne, didelphic and unicorn.)
  • previous implantation failures.
  • cysts, polyps or uterine tumors.
  • Pelvic inflammatory disease.
  • Obesity (Women with a BMI> 30)
  • Thyroid Disease.
  • Diabetes mellitus. Renal or adrenal disease,
  • toxic habits (smoking, alcohol or drug abuse)

ICSI group Couples who undergo ICSI invoking the egg donation program. In addition, all donors oocytes must be of proven fertility, this being that should have been able to take shape within the egg donation program or naturally. The recipient women (patients) should not present

  • Endometriosis.
  • Uterine malformations (uterine septum, bicorne, didelphic and unicorn.)
  • previous implantation failures.
  • cysts, polyps or uterine tumors.
  • Pelvic inflammatory disease.
  • Obesity (Women with a BMI> 30)
  • Thyroid Disease.
  • Diabetes mellitus. Renal or adrenal disease,
  • toxic habits (smoking, alcohol or drug abuse)

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02671344


Locations
Layout table for location information
Spain
IVI Bilbao
Leioa, Vizcaya, Spain, 48940
Sponsors and Collaborators
IVI Bilbao
Fundación IVI
Investigators
Layout table for investigator information
Principal Investigator: Fernando Quintana IVI Bilbao
Layout table for additonal information
Responsible Party: IVI Bilbao
ClinicalTrials.gov Identifier: NCT02671344    
Other Study ID Numbers: 1406-BIO-036-FQ
First Posted: February 2, 2016    Key Record Dates
Last Update Posted: February 12, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided